In the fall of 1999, a young chemical engineer named Todd Zion left his job at Eastman Kodak to enroll in the Ph.D. program at the Massachusetts Institute of Technology.
While looking for a subject to research, Zion noticed a grant proposal, never funded, that another graduate student had written on the subject of drug delivery. One possibility mentioned in the proposal was the development of a kind of insulin that would automatically respond to changes in blood-sugar levels, becoming active only when needed to maintain healthy levels around the clock. If it worked, the sugar-sensitive version could transform the lives of the six million people with diabetes in the United States who use insulin. No longer would they have to test their blood-sugar levels multiple times per day and try to calculate how much insulin to take. The self-regulating insulin would curtail high sugar levels, which raise the risk of long-term complications, and eradicate, or at least reduce, the most dangerous short-term complication: hypoglycemia, when sugar levels fall so low that they can cause confusion, unconsciousness, seizures and even death.
“I thought, Wow, that is a really neat area in which to do research,” Zion told me. Other researchers had been trying for 20 years to make insulin work only when needed. The first to publish a study were the scientists Michael Brownlee and Anthony Cerami, who in 1979 embedded a sugar-encrusted form of insulin in a mesh pouch with a sugar-loving protein called lectin. The idea was that when blood-sugar levels were elevated, the lectin would bind to the sugar in the blood and allow the insulin to leak out; when sugar levels were normal, the lectin would bind to the sugar-encrusted insulin, keeping it inside the pouch. But the system was impractical, because the pouch would need to be implanted under the skin and periodically refilled. And the lectin, derived from the jack-bean plant, was toxic.
In his first three years at M.I.T., Zion used nanoscale molecular engineering to create an insulin-lectin gel that could be injected without the need for an implanted pouch, while also rejiggering the lectin to make it less toxic. “It worked great visually,” he said. When the gel was placed in a sugar solution, “you could see the outer edge getting clear and dissolving . . . almost like an ice cube melting in water.”
The problem was that, no matter how hard he tried to manipulate the gel, the insulin either leaked out too easily, even when sugar levels were low, or not easily enough, when sugar levels were high.
Zion knew there was another approach: changing the insulin molecule itself, to make it sensitive to blood-sugar levels directly. But, he said, “almost everyone in the field of drug discovery believed that you should never, ever change the insulin molecule. . . . From a regulatory point of view, as soon as you manipulate the molecule, you’ve created a new drug. It doesn’t matter if you’ve attached a single atom to it.” Doing so, he knew, would require years of clinical trials in preparation for a new-drug application submission to the F.D.A. “That’s the only reason people were afraid.”
Zion’s trick was to attach a chemical arm — a short chain of sugars — directly onto the insulin molecule. (Attaching sugar to insulin? “Yes, it is a bit ironic,” he concedes.) The beauty of this approach is that it permits the insulin to latch directly onto the sugar-loving lectin in the gel — but only as needed. When blood-sugar levels are high, the lectin hooks up with any sugar floating freely from the blood, allowing the insulin molecule to do its normal job of connecting with insulin receptors on the surface of cells. (That is how insulin lowers blood-sugar levels, by merging with a cell’s insulin receptor and unlocking the cell membrane to allow sugar in.) When the sugar gets swallowed up by cells, lowering levels in the blood, the only remaining sweet for the lectin to attach to is the altered insulin’s sugar arm. Handcuffed to the lectin, the insulin can’t bind to insulin receptors. And so the insulin stops working to lower blood-sugar levels precisely when it’s no longer needed, because its sugar chain is held hostage by the lectin.
Zion called his new chemical creation smart insulin. In 2003, after testing it in rats, he won M.I.T.’s annual Entrepreneurship Competition. With the $30,000 prize money, he started a company called SmartCells and tried to see if he could make it work well enough to test it in humans.
The Latest on: Inventing drugs
[google_news title=”” keyword=”Inventing drugs” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Inventing drugs
- Incredible Inventions: Innovations That Changed The Worldon March 2, 2024 at 6:00 am
Welcome to a world where imagination knows no bounds and human ingenuity has the power to reshape the course of history.
- Is the famous weight-loss drug coming to India soon? What we know so faron February 28, 2024 at 10:01 pm
US drug maker Eli Lilly plans to launch its weight-loss drug Zepbound, also known as Mounjaro, in India next year. Here’s what we know ...
- Inventive step hurdles for biotech and pharmaceutical inventions in Japanon February 28, 2024 at 3:59 pm
In such a case, the combination of known drugs is filed in an application as a new invention. Whether the combination of known drugs can jump over the inventive step hurdle is a key issue to be ...
- Congressional efforts to lower drug costs keep falling short. Here's whyon February 28, 2024 at 11:45 am
The Inflation Reduction Act discourages biotech firms from investing the time and money necessary to develop biosimilars. That should change.
- Female Belmarsh prison officer who derailed murder trial by inventing false confession after killer showered her with money and gifts is jailed for nearly five yearson February 28, 2024 at 10:01 am
The pair had been texting while Ali was in prison and he had promised her a car while his relatives took her out for meals and supplied her with drugs. In a message to a friend she said ...
- Eli Lilly expects to launch obesity drug in India next year, says CEOon February 27, 2024 at 11:48 pm
The global market for these treatments is expected to reach at least $100 billion by the end of the decade, according to analyst estimates ...
- A Biden proposal to lower the cost of drugs threatens to upend Pennsylvania’s high-tech economy | Opinionon February 26, 2024 at 5:53 am
I am dismayed by the Biden administration’s attempt to disrupt this system and the decades-long consensus surrounding Bayh-Dole.
- When AI Helps Generate Inventions, Who Is the Inventor?on February 23, 2024 at 1:19 pm
AI advancements will contribute more and more significantly to the invention processes, blurring the lines of inventive contribution and raising the question of whether AI should be considered a joint ...
- Venture Capitalists Want Drug Prices to Stay Highon February 21, 2024 at 4:06 am
As the Biden administration launches a long-awaited fight to lower prices of lifesaving drugs developed with public funding, a formidable industry opponent of the effort has emerged: venture capital ...
- March-In Guidance For Publicly Funded Drugs: A Necessary Safety Net For Patientson February 20, 2024 at 5:03 am
March-in rights, Medicare drug price negotiation, and government patent use are each limited steps, but together they represent a new and growing effort to rein in the unparalleled pricing power of ...
via Bing News